A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study to Evaluate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507410-27-00

Acronym

UPB-CP-04

Enrollment

182

Registered

2024-04-30

Start date

2024-06-19

Completion date

Unknown

Last updated

2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Asthma

Brief summary

AAER over 60 weeks of treatment Annualized Asthma Exacerbation Rate (AAER) over 60 weeks of treatment

Detailed description

Change from baseline to Week 60 in pre-BD FEV1, Change from baseline to Week 60 in FeNO, Change from baseline to Week 60 in ACQ-6

Interventions

DRUGVerekitug (UPB-101)

DRUGVeritikug (UPB-101) matching solution for subcutaneous injection with no active treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
AAER over 60 weeks of treatment Annualized Asthma Exacerbation Rate (AAER) over 60 weeks of treatment	—

Secondary

Measure	Time frame
Change from baseline to Week 60 in pre-BD FEV1, Change from baseline to Week 60 in FeNO, Change from baseline to Week 60 in ACQ-6	—

Countries

Bulgaria, Czechia, Germany, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026